CLINICAL TRIALS PROFILE FOR BOSULIF
✉ Email this page to a colleague
All Clinical Trials for Bosulif
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02228382 ↗ | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | Terminated | Developmental Therapeutics Consortium | Phase 4 | 2014-11-07 | The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors). |
| NCT02228382 ↗ | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | Terminated | Pfizer | Phase 4 | 2014-11-07 | The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors). |
| NCT02269267 ↗ | The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | Completed | Barbara Ann Karmanos Cancer Institute | Phase 2 | 2014-12-18 | This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication. |
| NCT02269267 ↗ | The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | Completed | Dana-Farber Cancer Institute | Phase 2 | 2014-12-18 | This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication. |
| NCT02269267 ↗ | The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | Completed | Duke Cancer Institute | Phase 2 | 2014-12-18 | This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Bosulif
Condition Name
Clinical Trial Locations for Bosulif
Trials by Country
Clinical Trial Progress for Bosulif
Clinical Trial Phase
Clinical Trial Sponsors for Bosulif
Sponsor Name
